Infant Bacterial Therapeutics AB (STU:9IB) Current Deferred Taxes Liabilities : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Infant Bacterial Therapeutics AB's current deferred tax liabilities for the quarter that ended in Sep. 2024 was €0.00 Mil.

Infant Bacterial Therapeutics AB Current Deferred Taxes Liabilities Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Current Deferred Taxes Liabilities Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Taxes Liabilities

Get a 7-Day Free Trial

Infant Bacterial Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Infant Bacterial Therapeutics AB Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines